Abbott renal stenting trial
This article was originally published in The Gray Sheet
Abbott enrolls first patient Sept. 25 in a U.S. trial for its RX Herculink Elite renal stent system. The 50-site HERCULINK single-arm study is expected to enroll 202 patients with renal artery stenosis who have not responded to drug treatment for hypertension by early 2009. Primary follow-up of patients implanted with the cobalt chromium stent will be at nine months, with additional analyses out to three years. CMS is in the process of reconsidering its national coverage policy for renal stenting, in part due to a perceived lack of evidence as to its efficacy (1"The Gray Sheet" July 23, 2007, p. 18)
You may also be interested in...
CMS' Medicare Evidence Development Coverage Advisory Committee (MedCAC) could not reach consensus on whether Medicare coverage of angioplasty and stenting to treat renal artery disease should be limited to patients in clinical trials
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.